Cancer protein’s surprising role as memory regulator

	Tweet

Scientists at Dana-Farber Cancer Institute and Harvard Medical School have found that a common cancer protein leads a second, totally different life in normal adult brain cells: It helps regulates memory formation and may be implicated in Alzheimer’s disease.

Cyclin E is a well-known culprit that drives many types of solid tumors and blood cancers. The report, published online in Developmental Cell, is the first revelation that cyclin E has a crucial role in the formation of nerve connections, or synapses, in the brain. Synapses are tiny connections between brain cells where memories are stored.

“This protein has a double life,” said Peter Sicinski, PhD, a cancer biologist at Dana-Farber and senior author of the publication. “It is overexpressed in many different cancers, but it also is expressed in high levels in the human brain. We have found that cyclin E is needed for memory formation and is a very important player.”

The researchers found potential evidence linking cyclin E to Alzheimer’s disease, because it binds to an enzyme called Cdk5 that is involved in memory.

“There is good evidence that hyperactivity of Cdk5 contributes to Alzheimer’s disease and inhibiting this enzyme can ameliorate symptoms in animals,” said Sicinski, who is also a professor of Genetics at Harvard Medical School. “Manipulating cyclin E levels might be another way to accomplish this.”

The scientists didn’t test cyclin E in Alzheimer’s mice, but they did show that when cyclin E binds to Cdk5 molecules, it locks them away in an unusable form. Moreover, when the researchers reduced cyclin E levels in mouse brain cells, fewer nerve connections formed and the animals’ memories suffered.

Cyclins are a family of related proteins found in dividing cells. They serve as biological switches, controlling a cell’s progression from one phase of its life cycle to the next. The actual signals to exit one phase and enter the next are issued by enzymes called cyclin-dependent kinases, or Cdks, that bind to cyclins.

Many types of cancer cells, including breast, ovarian, colon, and blood cancers, are driven by the overexpression of cyclin E, which acts like a car’s accelerator pressed to the floor, speeding the cells through their growth-and-division cycle and allowing tumors to form and spread.

Though cyclin E is mainly found in dividing cells, researchers discover about a decade ago that cyclin E is also plentiful in adult, differentiated brain cells. But what it was doing there, no one knew.

In the current Developmental Cell paper, Junko Odajima, PhD, a postdoctoral fellow in the Sicinski laboratory and the paper’s co-lead author (with Zachary P. Wills, PhD, from Harvard Medical School), showed that cyclin E in the brain attaches itself to the Cdk5 enzyme. When cyclin E molecules bind to and inactive Cdk5, synapses formation is increased, and, presumably, memory function improves.

Odajima tested this idea using a standard memory and learning test in which mice swimming in water must find a submerged platform to rest on, and remember its location in subsequent trials. The researchers then move the platform, requiring the animals to “forget” its previous location and learn and remember the new one.

As their hypothesis had suggested, mice deficient in cyclin E performed worse than rodents who had a normal amount of cyclin E. This contrast highlighted the importance of cyclin E for learning and memory.

Whether cyclin E levels rise and fall in the mouse brain during learning tasks is a topic of further research, said the scientists, who also plan to determine whether abnormal cyclin E levels can be linked to neurological diseases and learning disorders.

###

Other authors on the publication include Jarrod Marto, PhD, of Dana-Farber, Michael E. Greenberg, PhD, of Harvard Medical School, and Stephen J. Moss from Tufts University School of Medicine.

The National Institutes of Health supported the research.

Dana-Farber Cancer Institute is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute. It provides adult cancer care with Brigham and Women’s Hospital as Dana-Farber/Brigham and Women’s Cancer Center and it provides pediatric care with Children’s Hospital Boston as Dana-Farber/Children’s Hospital Cancer Center. Dana-Farber is the top ranked cancer center in New England, according to U.S. News & World Report, and one of the largest recipients among independent hospitals of National Cancer Institute and National Institutes of Health grant funding.

###

Contact: Bill Schaller

617-632-5357
Dana-Farber Cancer Institute

RELATED STORIES:
Scientists report first step in strategy for cell replacement therapy in Parkinson’s disease   Humor as effective as medication in treating agitation in dementia   REM Sleep Disorder Doubles Risk of Mild Cognitive Impairment, Parkinson’s, Study Finds   Parkinson’s Disease Stopped in Animal Model   Two Proteins Needed to Turn on Dementia   Exercise may help prevent brain damage caused by Alzheimer’s disease   Stem cell study offers hope for Parkinson’s patients   Increased arm swing asymmetry is early sign of Parkinson’s disease   New Guidelines on Genetic Counseling and Testing for Alzheimer Disease   Is Alzheimer’s Caused by Contagious Proteins?   Test to predict dementia risk   Roche drug shows promise in early Alzheimer’s   UCLA Memory Fitness Program Improves Memory Abilities of Oldest Adults   Psych Drugs Linked to MI Risk in Dementia   Top scientist slams Australia’s dementia funding

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]